TriaGen Wealth Management’s AbbVie ABBV Stock Holding History

TriaGen Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$554K	Buy	+2,200	New	+$473K	0.14%	121

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TriaGen Wealth Management's ABBV Position: Q2 2026 in Review

TriaGen Wealth Management increased its AbbVie (ABBV) stake by 301% in Q2 2026, buying an estimated $2.02M and bringing the position to 12,498 shares worth $3.15M. The position accounts for 0.79% of the portfolio, ranked #26.

TriaGen Wealth Management first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

TriaGen Wealth Management held 12,498 shares of AbbVie worth $3.15M as of Q2 2026.
TriaGen Wealth Management bought 9,378 AbbVie shares in Q2 2026, an estimated $2.02M.
AbbVie made up 0.79% of TriaGen Wealth Management's portfolio in Q2 2026, its #26 holding.
TriaGen Wealth Management first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TriaGen Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.